Jesus G. Berdeja, MD | Authors


Cilta-cel Shows Deep and Durable Responses for R/R Multiple Myeloma

June 22, 2022

Jesus G. Berdeja, MD, director of multiple myeloma research at Sarah Cannon Research Institute and hematology specialist at Tennessee Oncology, discusses the results of the CARTITUDE-1 trial for chimeric antigen receptor T-cell therapy with the newly-approved agent ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.

Combination of Panobinostat and Carfilzomib in Relapsed or Relapsed/Refractory Multiple Myeloma

June 19, 2015

Jesus G. Berdeja, MD, director of Myeloma Research, senior investigator, Hematologic Malignancies Principal Investigator, Sarah Cannon Research Institute, discusses a phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma.